| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Chief Scientific Officer
1 company
Tactic Pharma LLC is a Chief Executive Officer at Monopar Therapeutics. Recent SEC Form 4 filings include 1 buy and 7 sells.
Estimated insider holdings value: $17.3M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2025 | MNPR Monopar Therapeutics | Chief Executive Officer | Sell | 550,229 | $63.61 | $34,999,956.64 | -66.9% | -3.5% | - | |
| Apr 2, 2025 | MNPR Monopar Therapeutics | Chief Executive Officer | Sell | 33,334 | $35.00 | $1,166,690.00 | -3.9% | -12.9% | +43.1% | |
| Feb 11, 2021 | MNPR Monopar Therapeutics | Chief Scientific Officer | Sell | 125,000 | $14.64 | $1,830,619.84 | -11.0% | - | - | |
| Dec 18, 2019 | MNPR Monopar Therapeutics | Chief Scientific Officer | Buy | 125,000 | $8.00 | $1,000,000.00 | +75.0% | - | - |